Literature DB >> 16684224

Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism?

Yoshihiro Tominaga1, Daijyo Inaguma, Susumu Matsuoka, Hideki Tahara, Kazutaka Kukita, Satoshi Kurihara, Noritaka Onoda, Yoshinari Tsuruta, Syuichi Tsutsui, Kazumichi Ohta, Morimasa Kuwahara, Motoko Tanaka, Yoshiki Nishizawa.   

Abstract

We evaluated the relationship between the volume of parathyroid glands estimated by ultrasonography (US) and response of 22-oxa calcitriol (Maxacalcitol, OCT) in patients with secondary hyperparathyroidism (2HPT) to evaluate whether the volume can be a predictor of the OCT response. Eleven institutes participated in this study. Ninety-four patients with advanced 2HPT were enrolled. The volume of the parathyroid glands were estimated by US before and 6 months after OCT treatment. The response of OCT treatment was classified into three groups (Group A: i-PTH < 300 pg/mL; Group B: 300 pg/mL < or = i-PTH < 500 pg/mL; Group C: i-PTH > or = 500 pg/mL). Forty-eight patients were in Group A, 28 patients in Group B, and 18 patients in Group C. The PTH levels at the beginning and 6 months were 458.3-199.1 pg/mL (P < 0.0001) in Group A, 524.6-403.2 pg/mL (P = 0.007) in Group B and 736.7-613.6 pg/mL (ns) in Group C, respectively. The volume of the largest gland in Group B was significantly larger than that in Group A (96.2 vs. 343.2 mm3: P < 0.001). Clinical factors affecting response of OCT was evaluated by logistic regression analysis and only the volume of the largest gland was a significant factor. In the patients whose volume was less than 300 mm3, the OCT response was significantly effective. We conclude that the glandular volume of the largest parathyroid gland estimated by US can be a useful factor to predict the OCT response in patients with moderate or severe renal HPT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684224     DOI: 10.1111/j.1744-9987.2006.00364.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  15 in total

Review 1.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

2.  Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.

Authors:  Masahiro Yamamoto; Hiroaki Ogata; Masahide Mizobuchi; Noriyo Yoshida; Chiaki Kumata-Maeta; Fumihiko Koiwa; Kanji Shishido; Eriko Kinugasa
Journal:  Clin Exp Nephrol       Date:  2011-10-20       Impact factor: 2.801

Review 3.  Regulation of parathyroid function in chronic kidney disease (CKD).

Authors:  Masafumi Fukagawa; Shohei Nakanishi; Hideki Fujii; Yasuhiro Hamada; Takaya Abe
Journal:  Clin Exp Nephrol       Date:  2006-09       Impact factor: 2.801

4.  Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.

Authors:  Hirotaka Komaba; Shohei Nakanishi; Akira Fujimori; Motoko Tanaka; Jeongsoo Shin; Koji Shibuya; Masato Nishioka; Hirohito Hasegawa; Takeshi Kurosawa; Masafumi Fukagawa
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-26       Impact factor: 8.237

5.  Parathyroid-gland ultrasonography in clinical and therapeutic evaluation of renal secondary hyperparathyroidism.

Authors:  C Vulpio; M Bossola; S C Magalini; P Silvestri; G Fadda; M Ciliberti; M L D'Andrea; G Maresca
Journal:  Radiol Med       Date:  2012-10-22       Impact factor: 3.469

Review 6.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

7.  Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism.

Authors:  Kiyoko Hosaka; Junichiro James Kazama; Suguru Yamamoto; Yumi Ito; Noriaki Iino; Hiroki Maruyama; Akihiko Saito; Ichiei Narita; Fumitake Gejyo
Journal:  J Bone Miner Metab       Date:  2008-02-27       Impact factor: 2.626

Review 8.  Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

9.  Clinical significance of parathyroid intervention on CKD-MBD management.

Authors:  Hiroaki Ogata; Masahide Mizobuchi; Fumihiko Koiwa; Eriko Kinugasa; Tadao Akizawa
Journal:  NDT Plus       Date:  2008-08

10.  New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients.

Authors:  Noritaka Onoda; Masafumi Fukagawa; Yoshihiro Tominaga; Masafumi Kitaoka; Tadao Akizawa; Fumihiko Koiwa; Takatoshi Kakuta; Kiyoshi Kurokawa
Journal:  NDT Plus       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.